| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Biological Sciences, University of Maryland, Baltimore, MD 21250
MHC class II-restricted tumor Ags presented by class II+ tumor cells identified to date are derived from proteins expressed in the cytoplasm or plasma membrane of tumor cells. It is unclear whether MHC class II+ tumor cells present class II-restricted epitopes derived from other intracellular compartments, such as nuclei and/or mitochondria, and whether class II+ tumor cells directly present Ag in vivo. To address these questions, a model Ag, hen egg lysozyme, was targeted to various subcellular compartments of mouse sarcoma cells, and the resulting cells were tested for presentation of three lysozyme epitopes in vitro and for presentation of nuclear Ag in vivo. In in vitro studies, Ags localized to all tested compartments (nuclei, cytoplasm, mitochondria, and endoplasmic reticulum) are presented in the absence invariant chain and H-2M. Coexpression of invariant chain and H-2M inhibit presentation of some, but not all, of the epitopes. In vivo studies demonstrate that class II+ tumor cells, and not host-derived cells, are the predominant APC for class II-restricted nuclear Ags. Because class II+ tumor cells are effective APC in vivo and probably present novel tumor Ag epitopes not presented by host-derived APC, their inclusion in cancer vaccines may enhance activation of tumor-reactive CD4+ T cells.
This article has been cited by other articles:
|
|
 |
|
  Y. Su, G. Carey, M. Maric, and D. W. Scott B Cells Induce Tolerance by Presenting Endogenous Peptide-IgG on MHC Class II Molecules via an IFN-{gamma}-Inducible Lysosomal Thiol Reductase-Dependent Pathway J. Immunol., July 15, 2008; 181(2): 1153 - 1160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Bosch, J. A. Thompson, M. K. Srivastava, U. K. Iheagwara, T. G. Murray, M. Lotem, B. R. Ksander, and S. Ostrand-Rosenberg MHC Class II-Transduced Tumor Cells Originating in the Immune-Privileged Eye Prime and Boost CD4+ T Lymphocytes that Cross-react with Primary and Metastatic Uveal Melanoma Cells Cancer Res., May 1, 2007; 67(9): 4499 - 4506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Sinzger, K. Eberhardt, Y. Cavignac, C. Weinstock, T. Kessler, G. Jahn, and J.-L. Davignon Macrophage cultures are susceptible to lytic productive infection by endothelial-cell-propagated human cytomegalovirus strains and present viral IE1 protein to CD4+ T cells despite late downregulation of MHC class II molecules J. Gen. Virol., July 1, 2006; 87(7): 1853 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Mortara, P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F. A. Procopio, A. Comes, L. Zardi, S. Ferrini, and R. S. Accolla CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory. Clin. Cancer Res., June 1, 2006; 12(11): 3435 - 3443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Dolan, K. D. Gibbs Jr., and S. Ostrand-Rosenberg Tumor-Specific CD4+ T Cells Are Activated by "Cross-Dressed" Dendritic Cells Presenting Peptide-MHC Class II Complexes Acquired from Cell-Based Cancer Vaccines J. Immunol., February 1, 2006; 176(3): 1447 - 1455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Thompson, S. K. Dissanayake, B. R. Ksander, K. L. Knutson, M. L. Disis, and S. Ostrand-Rosenberg Tumor Cells Transduced with the MHC Class II Transactivator and CD80 Activate Tumor-Specific CD4+ T Cells Whether or Not They Are Silenced for Invariant Chain Cancer Res., January 15, 2006; 66(2): 1147 - 1154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, N. Tuera, and S. Ostrand-Rosenberg Presentation of Endogenously Synthesized MHC Class II-Restricted Epitopes by MHC Class II Cancer Vaccines Is Independent of Transporter Associated with Ag Processing and the Proteasome J. Immunol., February 15, 2005; 174(4): 1811 - 1819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. D. Chamuleau, Y. Souwer, S. M. van Ham, A. Zevenbergen, T. M. Westers, J. Berkhof, C. J. L. M. Meijer, A. A. van de Loosdrecht, and G. J. Ossenkoppele Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome Cancer Res., August 15, 2004; 64(16): 5546 - 5550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Muntasell, M. Carrascal, I. Alvarez, L. Serradell, P. van Veelen, F. A. W. Verreck, F. Koning, J. Abian, and D. Jaraquemada Dissection of the HLA-DR4 Peptide Repertoire in Endocrine Epithelial Cells: Strong Influence of Invariant Chain and HLA-DM Expression on the Nature of Ligands J. Immunol., July 15, 2004; 173(2): 1085 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy Cancer Res., March 1, 2004; 64(5): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Dolan, T. P. Phelan, D. Ilkovitch, L. Qi, W. F. Wade, T. M. Laufer, and S. Ostrand-Rosenberg Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines J. Immunol., January 15, 2004; 172(2): 907 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Becart, N. Setterblad, S. Ostrand-Rosenberg, S. J. Ono, D. Charron, and N. Mooney Intracytoplasmic domains of MHC class II molecules are essential for lipid-raft-dependent signaling J. Cell Sci., June 15, 2003; 116(12): 2565 - 2575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Le Roy, M. Baron, W. Faigle, D. Clement, D. M. Lewinsohn, D. N. Streblow, J. A. Nelson, S. Amigorena, and J.-L. Davignon Infection of APC by Human Cytomegalovirus Controlled Through Recognition of Endogenous Nuclear Immediate Early Protein 1 by Specific CD4+ T Lymphocytes J. Immunol., August 1, 2002; 169(3): 1293 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pilch, H. Hohn, C. Neukirch, K. Freitag, P. G. Knapstein, B. Tanner, and M. J. Maeurer Antigen-Driven T-Cell Selection in Patients with Cervical Cancer as Evidenced by T-Cell Receptor Analysis and Recognition of Autologous Tumor Clin. Vaccine Immunol., March 1, 2002; 9(2): 267 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Qi and S. Ostrand-Rosenberg H2-O Inhibits Presentation of Bacterial Superantigens, but Not Endogenous Self Antigens J. Immunol., August 1, 2001; 167(3): 1371 - 1378. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
